SynBioBeta Speaker
Laura Glickman
Adjuvia Therapeutics
Co-Founder & CEO
Dr. Laura Hix Glickman, PhD, Co-Founder and CEO for Adjuvia Therapeutics, has over 30 years ofacademic and biotech experience developing vaccines, small molecules, enzyme-based therapeutics and nucleic acid delivery platforms to treat cancer, infectious disease, autoimmunity, mitochondrial dysfunction, and hemophilia.She has previously served as Founder, Executive, Board Member, Advisor and Scientific Lead for multiple public and private biotech companies: Actym Therapeutics (BIVF, Panacea Ventures, Illumina Ventures, JLO Ventures), Aduro Biotech (NASDAQ: ADRO), Catalyst Biosciences (NASDAQ: CBIO), Hawaii Biotech,Cardax Pharmaceuticals (NASDAQ:CDXI), Selva Therapeutics, Allos, OptiGenix, Immunitas Consulting, and is a Berkeley SkyDeck Key Advisor and Member of the Bio Selection Committee.In 2020, Dr. Glickman was named the #5 top-ranked female Series A Founder in the U.S. across all industries by Female Founders Fund, with an oversubscribed Series A of $34MM for Actym. She was also named the 2022 California Top 101 Presidents in the Biotechnology Space by Best Startup US.Dr. Glickman has 20 issued patents and multiple pending applications, over 20 research publications, and has successfully filed multiple IND applications to the FDA. As an undergraduate at UC Berkeley, she double majored in Molecular & Cell Biology and Psychology and is a proud contributor to Berkeley’s global status as #1 institution worldwide for venture-backed startups founded by undergraduate alumni. She earned her PhD in Cancer Immunology from Northwestern University’s Feinberg School of Medicine, where she was a Department of Defense Predoctoral Fellow studying “Mechanisms of Immune Suppression during Breast Cancer Metastasis.” She was among the 30 top Northwestern graduate students selected to participate in the Kellogg Business School’s Management for Scientists and Engineers Program, where she earned a certificate MBA.
